Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22516435 | 0.91 | IDO1 (0.54) | IDO1NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL20767284 | 0.90 | IDO1 (0.73) | IDO1 | |
| SCHEMBL21116109 | 0.88 | IDO1 (0.51) | IDO1KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL20767264 | 0.87 | IDO1 (0.59) | IDO1 | |
| SCHEMBL20780527 | 0.87 | IDO1 (0.63) | IDO1 | |
| SCHEMBL20780526 | 0.86 | IDO1 (0.65) | IDO1 | |
| SCHEMBL20780549 | 0.86 | IDO1 (0.62) | IDO1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL20767352 | 0.85 | IDO1 (0.61) | IDO1 | |
| SCHEMBL20767339 | 0.85 | IDO1 (0.63) | IDO1 | |
| SCHEMBL20767290 | 0.84 | IDO1 (0.54) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3672970-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885AHR 1044/4885KDM4E 4029/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885AHR 1044/4885KDM4E 4029/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885AHR 1044/4885KDM4E 4029/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885AHR 1044/4885KDM4E 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.